Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Projects Update

29 Sep 2008 07:00

RNS Number : 5036E
ViaLogy PLC
29 September 2008
 



ViaLogy Plc ("ViaLogy" or "the Company")

Projects Update

Pasadena, California - 29 September, 2008Vialogy PLC (AIM: VIY), the AiM-listed technology company, is pleased to announce significant developments in three of its major projects. 

Software installation in military base

The Company has been awarded a sub-contract from a major US defense system integrator for the insertion of ViaLogy's sensor interoperability platform software into an operating military base security system. ViaLogy will integrate the multiple perimeter surveillance systems on the base, simplifying operations and eliminating system failure in security deployment. 

More detailed information on the project and the names of the systems integrator firm and the specific military base cannot be disclosed for national security reasons.

In addition, SPM® was recently deployed by Los Angeles County first responders at a major sports event attended by over 90,000 fans to demonstrate and assess effectiveness in providing advance warning and crisis management in the event of a chemical or biological terrorist event. Following this success, LA County also deployed SPM to co-ordinate security and surveillance at the 60th Emmy Awards ceremony in Los Angeles. 

"The diversity of these SPM applications helps to position the product as the certified CBRNE (Chemical, Biological, Radiological, Nuclear and Explosive detection) and physical security sensor integration engine for purchases of enterprise-grade systems. We anticipate future customers will include state, local and federal procurement agencies, including the Department of Homeland Security, and system integrator firms", said Terry Bond, ViaLogy's Chairman.

New dates set for Oil & Gas validation

Hurricane Ike has caused a brief postponement of the ViaLogy-Atascosa Engineering partnership plans to drill its first well and thereby prove the value of ViaLogy's Quantum Resonance Interferometry (QRI™) technology which is being used to determine the oil reservoir's location, capacity and porosity, as well as the exact drill site. This adaptation of QRI is branded QuantumRD.

"Ike's unpredictable progress through Texas meant we had to delay preparations for erecting the drilling equipment", said Mr. Bond. "At one point it appeared that the site, near San Antonio, would be in the eye of the storm. Fortunately it transpired the area was on the perimeter and we sustained minimal damage."

While the project is a pilot, this is a fully operational extraction site and a strike should substantiate the effectiveness of the technology in the oil discovery process. Drilling is now scheduled for mid-October and results will be available towards the end of that month.

Aerial pipeline surveys in October

The second imminent application for QRI, called QSUB™, will be used to determine exact geolocation and condition of underground oil and gas pipelines. Proof-of-concept flights by Sky Research Inc of Ashland, Oregon, www.skyresearch.com, organised by ViaLogy and its partner firm ASTFS, are scheduled for this October. The aim is for QSUB technology to analyse data from airborne synthetic aperture radar (SAR) and light detection and ranging (LIDAR) sensors. ViaLogy has received strong indications of interest from leading pipeline firms in the success of the proof-of-concept work and in purchase of the operational service when available.

"There are almost 3 million kilometres of buried pipeline in the US alone", said Mr. Bond. "A cost-effective means of providing exact pipeline location and status is in high demand by both pipeline firms and regulatory agencies. We believe that the latest radar equipment, combined with QSUB data analysis will enable this to be done by aerial surveys."

Ends

Further information from:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

Stockbroker - St. Helen's Capital PLC +44 (0) 20-7628 5582 

PR Consultants - Redleaf Communications 

Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESBRGDCLDDGGII
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.